Why rely on one method when three are better? Ezra CEO Emi Gal explains how combining imaging, liquid biopsy, and biomarkers creates a superior cancer screening protocol. He also shares how AI enables longitudinal tracking of lesions, reducing false positives and patient anxiety. Learn what makes Ezra’s approach uniquely effective in the fight against cancer.
